Cancer-focused genetic testing services provider NeoGenomics has launched two new tests: the NeoLAB Solid Tumor Monitor and the NeoLAB BTK Inhibitor Acquired Resistance test.
The NeoLAB Solid Tumor Monitor is designed to track genomic abnormalities in tumors using cfDNA and helps physicians evaluate a atient’s response to therapy.
The NeoLAB BTK Inhibitor Acquired Resistance test aims to predict resistance to Bruton tyrosine kinase inhibitors, which are associated with mutations in the BTK and PLCG2 genes. Patients with chronic lymphocytic leukemia, mantle cell lymphoma and diffuse large B-cell lymphoma are among those treated with BTK inhibitors.
Both tests use cell-free DNA from peripheral blood plasma, eliminating the need for tissue biopsies. — Michael Cipriano